Clinical Trial Update: Phase 2 Study of G-202 in Patients With Chemotherapy-Naïve Metastatic Castrate-Resistant Prostate Cancer [Phase 2]

View source ↗

Summary

A Phase 2 study of G-202 for chemotherapy-naïve metastatic castration-resistant prostate cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• G-202

Snippet

Sponsor: GenSpera, Inc. | Conditions: Prostate Cancer. | Phase 2 | Status: WITHDRAWN